Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • thepianistfroggollum@lemmynsfw.com
    link
    fedilink
    English
    arrow-up
    2
    arrow-down
    3
    ·
    1 year ago

    Ah, that was the era of omicron. We’re over 21 months and several variants past that now, and I was given the information about paxlovid last week.

    Also, that study only covers a single month in Israel in 2022 and only 2.6% of the sample was given paxlovid.